Table 5.
Summary of some of the nanocarriers that can be combined with gene therapy and chemotherapy for overcoming multidrug resistance in cancer.
| Target | Gene | Nanocarrier | Chemoagent | Drug-Resistant Cell Line | Reference |
|---|---|---|---|---|---|
| P-gp | siRNA | PDA-coated mesenchymal stem cell (MSC) | Doxorubicin | MCF-7/ADR | [136] |
| Chitosan nanoparticle | Doxorubicin | HepG2/ADR | [137] | ||
| Polymeric NP | Doxorubicin | MCF-7/ADR | [138] | ||
| mRNA | Molecular beacon-based micelle | Doxorubicin | OVCAR-8/ADR | [139] | |
| Survivin | siRNA | Hyaluronic acid NP | Cisplatin | A549/DDP | [140] |
| Bcl-2 | siRNA | Polymeric NP | Doxorubicin | HepG2/ADR MCF-7/ADR |
[141] |
| GAPDH | siRNA | Liposome | Paclitaxel | HeLa, MCF-7 | [142] |
| Autophagy | siRNA | Polymeric NP | Doxorubicin | A549/ADR | [143] |
| P-gp, Bcl-2, survivin | siRNA | Coordination polymerMOF | Cisplatin | SKOV-3 | [144] |